Karen A. Dawes - 15 May 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Director
Signature
/s/ Marc Baumgartner (Attorney in Fact)
Issuer symbol
RGEN
Transactions as of
15 May 2025
Transactions value $
$0
Form type
4
Filing time
19 May 2025, 15:27:23
Previous filing
14 Jun 2024
Next filing
11 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
DAWES KAREN A Director C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM /s/ Marc Baumgartner (Attorney in Fact) 19 May 2025 0001261506

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +973 +1.07% $0.00 92.1K 15 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +1.8K $0.00 1.8K 15 May 2025 Common Stock 1.8K $123.26 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Dawes was awarded 973 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 15, 2026, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 Award vests in full on the earlier of May 15, 2026, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Remarks:

Exhibit 24.1: Power of Attorney